CN102762195B - 前列腺素激动剂前药的稳定水性组合物及其使用方法 - Google Patents

前列腺素激动剂前药的稳定水性组合物及其使用方法 Download PDF

Info

Publication number
CN102762195B
CN102762195B CN201080063225.1A CN201080063225A CN102762195B CN 102762195 B CN102762195 B CN 102762195B CN 201080063225 A CN201080063225 A CN 201080063225A CN 102762195 B CN102762195 B CN 102762195B
Authority
CN
China
Prior art keywords
composition
alkyl
compound
carboxylic acid
hydroxyalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080063225.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102762195A (zh
Inventor
R·M·伯克
W·B·艾姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102762195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN102762195A publication Critical patent/CN102762195A/zh
Application granted granted Critical
Publication of CN102762195B publication Critical patent/CN102762195B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080063225.1A 2009-12-09 2010-11-05 前列腺素激动剂前药的稳定水性组合物及其使用方法 Expired - Fee Related CN102762195B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26789709P 2009-12-09 2009-12-09
US61/267,897 2009-12-09
PCT/US2010/055590 WO2011071620A1 (en) 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof

Publications (2)

Publication Number Publication Date
CN102762195A CN102762195A (zh) 2012-10-31
CN102762195B true CN102762195B (zh) 2016-05-18

Family

ID=43503864

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080063225.1A Expired - Fee Related CN102762195B (zh) 2009-12-09 2010-11-05 前列腺素激动剂前药的稳定水性组合物及其使用方法

Country Status (16)

Country Link
US (2) US20110136872A1 (https=)
EP (1) EP2509582A1 (https=)
JP (2) JP5955774B2 (https=)
KR (1) KR20120106788A (https=)
CN (1) CN102762195B (https=)
AR (1) AR078929A1 (https=)
AU (1) AU2010328555B2 (https=)
CA (1) CA2783707A1 (https=)
CL (1) CL2012001545A1 (https=)
IL (1) IL220240A0 (https=)
MX (1) MX2012006622A (https=)
NZ (1) NZ600577A (https=)
RU (1) RU2012127869A (https=)
SG (1) SG181600A1 (https=)
TW (1) TW201138766A (https=)
WO (1) WO2011071620A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201900863T4 (tr) 2012-08-27 2019-02-21 Allergan Inc Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
KR101535825B1 (ko) 2012-09-25 2015-07-10 엘지디스플레이 주식회사 표시장치 및 이의 라인결함 검출방법
TR201902864T4 (tr) * 2014-02-20 2019-03-21 Allergan Inc Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
CA2962766A1 (en) 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228048A1 (en) * 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
EP2123278A1 (en) * 2007-02-07 2009-11-25 Teika Pharmaceutical Co., Ltd. Eye drop reparation comprising latanoprost

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
WO2000004898A1 (en) * 1998-07-21 2000-02-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
PL1759702T3 (pl) * 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem
CA2599425C (en) * 2005-03-10 2013-04-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
MY150518A (en) * 2008-04-24 2014-01-30 Allergan Inc Substituted gamma lactams as therapeutic agents
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050228048A1 (en) * 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
EP2123278A1 (en) * 2007-02-07 2009-11-25 Teika Pharmaceutical Co., Ltd. Eye drop reparation comprising latanoprost

Also Published As

Publication number Publication date
CL2012001545A1 (es) 2012-08-31
AR078929A1 (es) 2011-12-14
WO2011071620A1 (en) 2011-06-16
JP2013513606A (ja) 2013-04-22
IL220240A0 (en) 2012-07-31
NZ600577A (en) 2014-10-31
JP2016056207A (ja) 2016-04-21
US20160220677A1 (en) 2016-08-04
EP2509582A1 (en) 2012-10-17
SG181600A1 (en) 2012-07-30
TW201138766A (en) 2011-11-16
CN102762195A (zh) 2012-10-31
AU2010328555A1 (en) 2012-07-05
JP5955774B2 (ja) 2016-07-20
CA2783707A1 (en) 2011-06-16
RU2012127869A (ru) 2014-01-20
US20110136872A1 (en) 2011-06-09
KR20120106788A (ko) 2012-09-26
MX2012006622A (es) 2012-08-15
AU2010328555B2 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
CA2310661C (en) Ep2-receptor agonists as neuroprotective agents for the eye
US11723861B2 (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US20040213782A1 (en) Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP6813916B2 (ja) 薬学的組成物
JP2852057B2 (ja) 緑内症または高眼圧症治療剤
JP7474706B2 (ja) ４－フェニル酪酸を含有する老視の治療または予防剤
CN102946883A (zh) 治疗视网膜疾病的方法及眼用组合物
CN102762195B (zh) 前列腺素激动剂前药的稳定水性组合物及其使用方法
JP2021006548A (ja) ウルソデオキシコール酸を含有する老視の治療または予防剤
RU2672057C2 (ru) Ингибитор хориоретинальных нарушений
KR20170088875A (ko) 수술 후 안구 염증성 병태를 억제시키기 위한 전방내용의, 항―염증성 및 산동성 용액
US20120087864A1 (en) Method for diagnosing and/or evaluating retinal disease
US7696235B2 (en) EP2 receptor agonists for treating glaucoma
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
US20050282912A1 (en) Abnormal cannabidiols as neuroprotective agents for the eye
JP2022152866A (ja) コール酸またはコール酸誘導体を含有する老視の治療または予防剤
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
JP2009235069A (ja) ３’，５−ジ−２−プロペニル−（１，１’−ビフェニル）−２，４’−ジオールを有効成分として含有する視神経障害の予防又は治療剤
WO2010135404A1 (en) Ep2 receptor agonist from non-prostanoid structures designed as pge2 antagonists
WO2020166679A1 (ja) 眼圧下降用医薬組成物
EA051012B1 (ru) Соединения, являющиеся антагонистами trpa1 каналов, для применения при дегенеративных заболеваниях сетчатки
JP2026505378A (ja) 視覚を改善するためのα２アドレナリン作動薬
AU2013200669A1 (en) EP2 receptor agonists for treating glaucoma
JP2004182701A (ja) ヒドロキサム酸誘導体を有効成分とする眼組織血管新生阻害剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160518

Termination date: 20171105